MARKET

ARDX

ARDX

Ardelyx
NASDAQ
1.510
+0.140
+10.22%
After Hours: 1.460 -0.05 -3.31% 16:20 10/05 EDT
OPEN
1.350
PREV CLOSE
1.370
HIGH
1.540
LOW
1.330
VOLUME
4.05M
TURNOVER
0
52 WEEK HIGH
1.920
52 WEEK LOW
0.4902
MARKET CAP
233.50M
P/E (TTM)
-1.3339
1D
5D
1M
3M
1Y
5Y
Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on September 26, 2022, the compensat...
PR Newswire · 5d ago
Ardelyx Says On Sept. 19, 2022 Co. Received Letter From Nasdaq Confirming Co. Had Regained Compliance With Listing Requirement
-SEC Filing
Benzinga · 09/19 20:14
BRIEF-Ardelyx Inc Received Letter From Nasdaq Confirming That Co Had Regained Compliance With Nasdaq
BRIEF-Ardelyx Inc Received Letter From Nasdaq Confirming That Co Had Regained Compliance With Nasdaq
Reuters · 09/19 20:09
Ardelyx Says It Regained Compliance With Nasdaq's Minimum Bid Price
Ardelyx Says It Regained Compliance With Nasdaq's Minimum Bid Price
MT Newswires · 09/19 17:33
BRIEF-Deep Track Capital LP Reports 8.45% Passive Stake In Ardelyx Inc As Of September 02
BRIEF-Deep Track Capital LP Reports 8.45% Passive Stake In Ardelyx Inc As Of September 02
Reuters · 09/12 21:27
ARDX, BCLI and PIXY are among pre market gainers
Amylyx Pharmaceuticals (AMLX) +83% <a href="https://seekingalpha.co...
Seekingalpha · 09/08 12:21
Amylyx drives Reta, Ardelyx higher ahead of AdCom decision on ALS drug
The shares of clinical-stage biopharma companies Reata Pharmaceuticals (NASDAQ:<a href="https://seekingalpha.com/symbol/RETA?utm_medium=referral&utm_source=webull.com" title="Reata Pharmaceuticals, Inc." target=...
Seekingalpha · 09/07 17:41
Ardelyx to Participate in Upcoming Investor Conferences
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced its participation in the following upcomi...
PR Newswire · 09/06 12:00
More
About ARDX
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The Company's product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of hyperphosphatemia, a condition of elevated levels of phosphate in the blood, common among patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Webull offers kinds of Ardelyx Inc stock information, including NASDAQ:ARDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARDX stock methods without spending real money on the virtual paper trading platform.